CytoImmune Therapeutics to Present Preclinical Data Highlighting Potential of Novel TRACK-NK Cells to Selectively Target and Kill Hematologic and Solid Tumor Cancer Cells
MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced the appointment of Remus Vezan, M.D., Ph.D., as Chief Medical Officer. Dr. Vezan is an industry leader who has been responsible for the successful advancement of numerous cell therapies from early-stage development through commercialization, including one of the first U.S. Food and Drug Administration (FDA)- approved CAR T-cell therapies for hematologic malignancies.
LOS ANGELES & MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, and City of Hope, one of the largest cancer research and treatment organizations in the United States today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CYTO-102, a novel cellular therapy consisting of PD-L1-positive tumor-reactive TRACK-NKTM cells. The trial is assessing CYTO-102 as a monotherapy and in combination with atezolizumab in patients with relapsed/refractory non-small cell lung cancer (NSCLC).
MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of natural killer (NK) cell-based cancer therapies, announced new preclinical data supporting the therapeutic potential of its CYTO-102 and CYTO-201 programs as treatments for patients with cancer. New findings demonstrate the utility of its NK cell platform to generate off-the-shelf, tumor-reactive NK cell (TRACK-NK™) and chimeric antigen receptor (CAR) engineered NK cell (CAR-NK) therapies, that result in effective tumor cell killing with favorable tolerability for both solid and liquid tumors. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, being held April 8-13, 2022, in New Orleans.
MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced that Christina Coughlin, M.D., Ph.D., chief executive officer, will participate in the following April investor conferences:
MONROVIA, Calif. & TOA BAJA, Puerto Rico--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced the opening of the Company’s clinical cell manufacturing facility in Toa Baja, which was celebrated with a visit from the Governor of Puerto Rico, Pedro R. Pierluisi. The Secretary of Economic Development and Commerce, Manuel Cidre, and the Mayor of the municipality, Bernardo “Betito'' Márquez, were also in attendance during the opening of the facility.
MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of natural killer cell-based cancer therapies, today announced that the company will present preclinical data from its FLT3 CAR-NK cell program for acute myeloid leukemia and its TRACK-NK™ program for non-small cell lung cancer at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held April 8-13, 2022, in New Orleans.
Now as the new head honcho at CytoImmune as of Wednesday, the first-time CEO gets to work with a new type of cell therapy — CAR-NK cells, licensed from long-time NK cell researcher Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD). The results demonstrated that DMD patients on daily EMFLAZA performed better on key measures of physical function including the six-minute-walk test, key timed function tests, and the North Star Ambulatory Assessment than patients taking daily prednisone.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD). The results demonstrated that DMD patients on daily EMFLAZA performed better on key measures of physical function including the six-minute-walk test, key timed function tests, and the North Star Ambulatory Assessment than patients taking daily prednisone.